[go: up one dir, main page]

AU2002212236A1 - An hsp70 peptide stimulating natural killer (nk) cell activity and uses thereof - Google Patents

An hsp70 peptide stimulating natural killer (nk) cell activity and uses thereof

Info

Publication number
AU2002212236A1
AU2002212236A1 AU2002212236A AU1223602A AU2002212236A1 AU 2002212236 A1 AU2002212236 A1 AU 2002212236A1 AU 2002212236 A AU2002212236 A AU 2002212236A AU 1223602 A AU1223602 A AU 1223602A AU 2002212236 A1 AU2002212236 A1 AU 2002212236A1
Authority
AU
Australia
Prior art keywords
peptide
natural killer
cell activity
stimulating natural
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002212236A
Inventor
Gabriele Multhoff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2002212236A1 publication Critical patent/AU2002212236A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/07—Heat shock proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention relates to an immunostimulatory peptide derived from an Hsp70 protein and peptides comprising said immunostimulatory peptide. Furthermore the present invention pertains to polynucleotides encoding said peptide, vectors comprising said polynucleotides, fusion (poly)peptides comprising said peptide and compositions comprising said peptide. In addition the present invention relates to the use of said peptide, polynucleotide, vector or fusion (poly)peptide, for the preparation of pharmaceutical compositions for the treatment of diseases and for the stimulation of natural killer cell (NK cell) activity.
AU2002212236A 2000-09-13 2001-09-13 An hsp70 peptide stimulating natural killer (nk) cell activity and uses thereof Abandoned AU2002212236A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP00119933.0 2000-09-13
EP00119933 2000-09-13
PCT/EP2001/010593 WO2002022656A2 (en) 2000-09-13 2001-09-13 An hsp70 peptide stimulating natural killer (nk) cell activity and uses thereof
BE2009/0695A BE1019732A4 (en) 2000-09-13 2009-11-12 HSP70 PEPTIDE SIMULATING THE ACTIVITY OF NATURAL KILLING CELLS (NK) AND USES THEREOF.

Publications (1)

Publication Number Publication Date
AU2002212236A1 true AU2002212236A1 (en) 2002-03-26

Family

ID=47436345

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002212236A Abandoned AU2002212236A1 (en) 2000-09-13 2001-09-13 An hsp70 peptide stimulating natural killer (nk) cell activity and uses thereof

Country Status (8)

Country Link
US (2) US7517948B2 (en)
EP (1) EP1319023B8 (en)
AT (1) ATE430161T1 (en)
AU (1) AU2002212236A1 (en)
BE (1) BE1019732A4 (en)
DE (1) DE60138558D1 (en)
ES (1) ES2326114T3 (en)
WO (1) WO2002022656A2 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002212236A1 (en) * 2000-09-13 2002-03-26 Gabriele Multhoff An hsp70 peptide stimulating natural killer (nk) cell activity and uses thereof
IL148401A0 (en) * 2002-02-26 2002-09-12 Hadasit Med Res Service Hsp70-derived peptides and uses thereof in the diagnosis and treatment of autoimmune diseases
JP4699755B2 (en) * 2002-08-23 2011-06-15 ガブリエル ムルソフ， Use of granzyme B as an Hsp70 / Hsp70 peptide-dependent inducer of apoptosis in tumor cells
WO2005054868A1 (en) * 2003-12-05 2005-06-16 Multimmune Gmbh Compositions and methods for the treatment and diagnosis of neoplastic and infectious diseases
US7700737B2 (en) * 2003-12-05 2010-04-20 Multimmune Gmbh Therapeutic and diagnostic anti-Hsp70 antibodies
US20100034772A1 (en) * 2006-11-14 2010-02-11 Ralf Dressel Compositions and methods for immunotherapy
GB0705626D0 (en) * 2007-03-23 2007-05-02 Royal Veterinary College Method for enhancing sperm survival
CA3004867C (en) 2008-06-26 2020-09-15 Orphazyme Aps Use of hsp70 as a regulator of enzymatic activity
WO2012023631A1 (en) * 2010-08-19 2012-02-23 株式会社Eci Pharmaceutical composition for inhibiting proliferation of cancer cells which comprises heat shock protein (hsp) and eci301 polypeptide, and cancer treatment method using same
JP2013544263A (en) 2010-11-30 2013-12-12 オルファザイム エーピーエス Method for increasing intracellular activity of Hsp70
WO2014130759A1 (en) * 2013-02-21 2014-08-28 University Of Rochester Methods of using histamine receptor agonists and antagonists
JP6678676B2 (en) 2014-09-15 2020-04-08 オーファザイム エー／エス Arimoclomol formulation
TWI687434B (en) 2014-10-07 2020-03-11 日商賽多利克公司 Manufacturing method of pharmaceutical composition for treating or preventing cancer, immunity inducing agent, and antigen presenting cell using peptide from HSP70
JP6779909B2 (en) 2015-01-26 2020-11-04 セレクティスＣｅｌｌｅｃｔｉｓ Anti-CLL1-specific single-chain chimeric antigen receptor (scCAR) for cancer immunotherapy
CA2981468A1 (en) 2015-04-07 2016-10-13 Cytlimic Inc. Medicine
MX2018010961A (en) 2016-03-10 2019-03-28 Aperisys Inc Antigen-binding fusion proteins with modified hsp70 domains.
EP3442530A1 (en) 2016-04-13 2019-02-20 Orphazyme A/S Heat shock proteins and cholesterol homeostasis
PT3448382T (en) 2016-04-29 2020-11-20 Orphazyme As C/O Cobis As Arimoclomol for treating glucocerebrosidase associated disorders
WO2018037042A1 (en) * 2016-08-23 2018-03-01 Aimvion A/S Novel immunostimulating peptides
CN106317216B (en) * 2016-09-21 2019-07-19 南京农业大学 It is a kind of promote H9N2 avian influenza vaccine immune effect active peptide and application
EP3527216B1 (en) 2016-10-11 2024-02-14 NEC Corporation A medicine comprising a toll-like receptor agonist, lag-3 protein, a hsp70-derived peptide and a gpc3-derived peptide
EP3675877A1 (en) * 2017-08-31 2020-07-08 Multimmune GmbH Hsp70 based combination therapy
IL303026A (en) 2020-11-19 2023-07-01 Zevra Denmark As Processes for preparing arimoclomol citrate and its intermediates

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6268478B1 (en) * 1996-02-12 2001-07-31 Cedars-Sinai Medical Center Intracellular vitamin D binding protein
EP1066050B2 (en) 1998-03-27 2010-06-02 Gabriele Prof. Dr. Multhoff Application of hsp70 proteins
CN1057363C (en) 1998-07-10 2000-10-11 贺德新 All-intelligent multifunctional hydraulic extruding extender
CA2352286C (en) 1998-11-24 2011-07-12 Bristol-Myers Squibb Company Intracellular targeted delivery of compounds by 70 kd heat shock protein
AU2002212236A1 (en) * 2000-09-13 2002-03-26 Gabriele Multhoff An hsp70 peptide stimulating natural killer (nk) cell activity and uses thereof

Also Published As

Publication number Publication date
BE1019732A4 (en) 2012-12-04
ES2326114T3 (en) 2009-10-01
WO2002022656A2 (en) 2002-03-21
EP1319023B8 (en) 2009-07-15
EP1319023B1 (en) 2009-04-29
DE60138558D1 (en) 2009-06-10
US20040063173A1 (en) 2004-04-01
US7745399B2 (en) 2010-06-29
US20090239802A1 (en) 2009-09-24
WO2002022656A3 (en) 2002-09-26
EP1319023A2 (en) 2003-06-18
ATE430161T1 (en) 2009-05-15
US7517948B2 (en) 2009-04-14

Similar Documents

Publication Publication Date Title
EP1319023B8 (en) An hsp70 peptide stimulating natural killer (nk) cell activity and uses thereof
WO2003064449A3 (en) Bioactive keratin peptides
AU3368497A (en) Human dnase i hyperactive variants
EP2261247A3 (en) KDR peptides and vaccines comprising the same
BR0113491A (en) Isolated polynucleotide and polypeptide, expression vector, host cell, fusion protein, methods for stimulating and / or expanding tumor protein-specific T cells to stimulate an immune response in a patient, to treat cancer in a patient and to inhibit cancer development in a patient, isolated t-cell population, composition, and use of a component.
IL105554A0 (en) Peptides of human papilloma virus for use in human t cell response inducing compositions
WO2002044320A3 (en) Human elongase genes and uses thereof
TW200407425A (en) Human coagulation factor VII polypeptides
WO2000075173A3 (en) Peptide fragments of colostrinin
EP1350848A3 (en) T-cell membrane protein (TIRC7), gene encoding it and antibodies against it and uses thereof
HUP0100267A2 (en) Nucleic acid and amino acid sequences relating to helicobacter pylori and vaccine compositions thereof
WO2001034641A3 (en) Antimicrobial activity of the first cationic cluster of human lactoferrin
DE69534633D1 (en) IMPLANT AND VECTOR FOR THE TREATMENT OF PUBLIC DISEASES
WO2001049711A3 (en) Nucleic acids encoding (poly)peptides having chips activity
IL143956A (en) Chimeric polypeptide having the antigenic determinants of four proteins of l. infantum, polynucleotides encoding same, methods of production and use thereof in therapeutic compositions
UA84831C2 (en) Coagulation factor vii derivatives
RU99116976A (en) MYELOPEPTIDES AND THEIR THERAPEUTIC USE
WO2001053324A3 (en) Novel haptotactic peptides
CY1109617T1 (en) An HSP70 Peptide Stimulating the Activity of Natural Killer Cells (NK) and Its Uses
WO2003025014A3 (en) Use of peptides comprising post-translational modifications in the treatment of autoimmune pathologies
ATE420890T1 (en) BIOLOGICALLY ACTIVE PEPTIDES CONTAINING ISOLEUCYL-VALYL-THREONYL-ASPARAGINYL-THREONYL-THREONINE (IVTNTT).
WO2001098355A3 (en) Cgi-69 compositions and methods of use
ATE338063T1 (en) DIAGNOSTIC USES OF THE T-CELL PROTEIN TZON7, THE PEPTIDES DERIVED FROM IT, AND THE ANTIBODIES
AU2001263888A1 (en) Uses of tgap7 for the modulation of leucocyte activation
WO2004011496A3 (en) Novel t-cell proteins, peptides and antibodies derived therefrom and uses thereof